NCT06991712RecruitingPhase 2
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Comparisons of Nicotinamide Adenine Dinucleotide (NAD) Precursors for Neuroenhancement in Glaucoma Patients
Source: ClinicalTrials.gov · Last updated 26 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are: 1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function? Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo. Participants will: Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks. Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks. Provide blood samples before and after the intervention for measurement of NAD+ metabolites. Have safety monitored through clinical examination. This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- First submitted
- 16 May 2025
- Start date
- 19 May 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Christopher Kai Shun Leung
- Diseases
- Glaucoma
- NCT number
- NCT06991712
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 138
- From 19 May 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of NAD precursor supplements 14 days prior to baseline.
Other illness
- diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
- history of abnormal liver function within 12 months
- known allergy to NAD precursor supplement(s)
Other
- pathological myopia
- inability to perform reliable visual field
- suboptimal quality of OCT images
- diabetic retinopathy/maculopathy
- pregnancy or lactation
Who the study is looking for
- glaucoma patients
- age ≥ 18 years
- best corrected VA ≥20/40
- IOP \<21 mmHg
- visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HKU Eye Centre Coordinator of this site? Confirm its status | Wong Chuk Hang | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.